NCT05316805 China Type II Inflammatory Skin Disease Clinical Research and Standardized Diagnosis and Treatment Project
| NCT ID | NCT05316805 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking University First Hospital |
| Condition | Atopic Dermatitis Eczema |
| Study Type | OBSERVATIONAL |
| Enrollment | 100,000 participants |
| Start Date | 2021-08-31 |
| Primary Completion | 2031-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100,000 participants in total. It began in 2021-08-31 with a primary completion date of 2031-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In order to further improve the diagnosis and treatment level of type 2 inflammatory skin diseases, the National Clinical Center for Skin and Immune Diseases established a standardized diagnosis and treatment center for type 2 inflammatory skin diseases to systematically and effectively understand the current treatment status of patients with type 2 inflammatory skin diseases, as well as the efficacy and safety of various treatment methods during practices, so as to further improve the diagnosis and treatment level of type 2 inflammatory skin diseases and help patients with type 2 inflammatory skin diseases.
Eligibility Criteria
Inclusion Criteria: 1. Patients from the medical units that has passed the data review of the National Clinical Center for Skin and Immune Diseases (see the study sites for data collection for details); 2. patients diagnosed with type 2 inflammatory skin diseases (dermatitis/eczema, urticaria, pemphigoid, prurigo nodularis). Exclusion Criteria: 1. patients who fail to provide informed consent form; 2. patients who cannot complete the questionnaire independently or under the guidance of investigators
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05316805 clinical trial?
This trial is open to participants of all sexes, studying Atopic Dermatitis Eczema. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05316805 currently recruiting?
Yes, NCT05316805 is actively recruiting participants. Contact the research team at yangwang_dr@bjmu.edu.cn for enrollment information.
Where is the NCT05316805 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT05316805 clinical trial?
NCT05316805 is sponsored by Peking University First Hospital. The trial plans to enroll 100,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.